Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.65 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | IL1B | P01584 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.53 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23672337 | 0.94 | CRBN (0.63) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL22836598 | 0.93 | CRBN (0.63) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL22835222 | 0.92 | CRBN (0.62) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL22835885 | 0.90 | DDB1 (0.67) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25894864 | 0.90 | CRBN (0.62) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL23672426 | 0.89 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL23568011 | 0.89 | CRBN (0.68) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21997001 | 0.89 | CRBN (0.67) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25733191 | 0.88 | CRBN (0.60) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25878607 | 0.88 | CRBN (0.60) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240383887-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240316004-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-4333836-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2022236339-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4076520-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220054453-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| WO-2022027058-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | CRBN 39/4885DDB1 511/4885IKZF3 202/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF3 135/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | CRBN 70/4885DDB1 2951/4885IKZF3 252/4885 |
| US-20220054453-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | IRAK4, IRAK2, IRAK3 | CRBN 111/4885DDB1 291/4885IKZF3 51/4885 |
| US-20240383887-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK1, IRAK3 | CRBN 203/4885DDB1 384/4885IKZF3 272/4885 |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF3 135/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF3 135/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | CRBN 79/4885DDB1 2480/4885IKZF3 229/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF3 135/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF3 135/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | CRBN 322/4885DDB1 68/4885IKZF3 266/4885 |
| US-20240316004-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | IRAK4, IRAK2, IRAK3 | CRBN 111/4885DDB1 291/4885IKZF3 51/4885 |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF3 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.